Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Drug Discovery
- Diagnostic
- cardiac
- Therapeutic
- Genome
- Molecular
- Assay
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 324664
Upon acceptance of such compounds by Licensee, Licensor shall grant an exclusive license in the Territory under this Agreement to make, have made, use, sell, offer for sale and import certain Licensed Products throughout the Territory.
The License Grant for Development, Licensor grants a non-exclusive license in the Territory to use subject matter within the Licensor Technology solely for the purpose of performing internal development activities[, relating to the Development Candidates prior to exercise of Licensees Development Election, which activities are designed to facilitate the further development of such Development Candidates in the event of Licensees exercise of its Development Election.
For the Commercialization, upon Licensees exercise of its Development Election and acceptance of each Licensed Product, Licensor shall be hereby deemed to have granted, and hereby grants to Licensee, during the Term, the exclusive right and license in the Territory, with the right to grant sublicenses, under the Licensor Technology, to make, have made, use, sell, offer for sale and import such Licensed Products for any and all purposes.
Biotherapeutic Product shall mean any antibody, protein, gene product or antisense product which binds, modulates or regulates one or more Biotherapeutic Targets.
Biotherapeutic Target shall mean any Proposed Biotherapeutic Target which is excluded from the Development Program.
Patents are titled
Human ECT2 and methods of use;
Modulating Branching Morphogenesis through targeting FNG;
Modulating Branching Morphogenesis through targeting RANBP;
Modulating Branching Morphogenesis through targeting GC;
Modulating Branching Morphogenesis through targeting Dock;
Modulating Branching Morphogenesis through targeting Sec31;
Modulating Branching Morphogenesis through targeting MBM;
Modulating Branching Morphogenesis through targeting ALTI;
Modulating Branching Morphogenesis through targeting FRY;
Modulating Branching Morphogenesis through targeting PCBP;
Modulating Branching Morphogenesis through targeting EMP;
Modulating Branching Morphogenesis through targeting ALDEP;
ADSLs as modifiers of the p53 Pathway and methods of use;
P5CRS as modifiers of the p53 Pathway and methods of use; and,
Human ADAM-IO Inhibitors
Ephrin Receptor Inhibitors and Methods of Use
IPSCIO Record ID: 326967
Upon the expiration of a Development Election with respect to a Refused Candidate, Licensor shall [be deemed to have granted, and hereby does grant, a license under all of Licensors right and title to the Collaboration Technology that was (1) developed by GSK solely in connection with Licensor s activities under the Development Program, and (2) in existence as of the effective date of the expiration of the First Option Period with respect to such Refused Candidate and its related Included Compounds, solely to make, have made, use, sell, offer for sale and import such Refused Candidate or Included Compounds related thereto. Such license shall be exclusive, but only as to such Refused Candidate or Included Compounds, or, if Licensor cannot grant an exclusive license thereunder, it shall be non-exclusive.
Product shall mean a (i) Licensed Product; (ii) Returned Licensed Product; (iii) Licensor Product; (iv) Licensor Biotherapeutic Product; (v) Competitive Product; (vi) Licensee Licensed Product; (vii) a Change of Control Licensed Product; (viii) a SAC
Competitive Product; or (ix) Combination Product incorporating any of the foregoing products.
Biotherapeutic Product shall mean any antibody, protein, gene product or antisense product which binds, modulates or regulates one or more Biotherapeutic Targets.
Biotherapeutic Target shall mean any Proposed Biotherapeutic Target which is excluded from the Development Program.
Patents are titled
Human ECT2 and methods of use;
Modulating Branching Morphogenesis through targeting FNG;
Modulating Branching Morphogenesis through targeting RANBP;
Modulating Branching Morphogenesis through targeting GC;
Modulating Branching Morphogenesis through targeting Dock;
Modulating Branching Morphogenesis through targeting Sec31;
Modulating Branching Morphogenesis through targeting MBM;
Modulating Branching Morphogenesis through targeting ALTI;
Modulating Branching Morphogenesis through targeting FRY;
Modulating Branching Morphogenesis through targeting PCBP;
Modulating Branching Morphogenesis through targeting EMP;
Modulating Branching Morphogenesis through targeting ALDEP;
ADSLs as modifiers of the p53 Pathway and methods of use;
P5CRS as modifiers of the p53 Pathway and methods of use; and,
Human ADAM-IO Inhibitors
Ephrin Receptor Inhibitors and Methods of Use
IPSCIO Record ID: 121121
The parties desire to establish a technology sharing program that relates to its high throughput lead optimization technology, and Licensor will transfer to Licensee its proprietary technology that relates to genetics and molecular biology in C. elegans and Drosophila.
Licensor grants a limited, non-exclusive, non-transferable, worldwide, perpetual license to use and practice the Licensors Core Technology, Core Technology Patents, and any Improvement Inventions made solely by Licensor to the Licensees Core Technology solely for its own internal research and discovery efforts in the Field.
Licensor grants a limited, non-exclusive, non-transferable, world-wide, perpetual license to use, adapt, reproduce, modify, localize, and create derivative works of the FlyTag Database, provided that all such uses of the FlyTag Database are solely for Licensees internal or collaborative research purposes, are used in the same manner, and subject to the same terms and conditions, as apply to the FlyTag Database Research Results.
For Research Results, Licensor grants an exclusive, worldwide, royalty-bearing license to use Research Results pertaining to Selected Targets, Product Targets, Mammalian Targets and Pursued Disclosed Targets for research and drug discovery and development in the Field, and to research, develop, import, use, sell, offer for sell, and commercialize Collaboration Compounds, Licensed Products and New Indications in the Field.
For Target Patents, Licensor grants a non-exclusive, worldwide, royalty-bearing license under any Patents that are Controlled by Licensor or its Affiliates and claim any of the Research Results and/or any Selected Targets, Pursued Disclosed Targets or Mammalian Targets, solely to discover, research and develop Collaboration Compounds, Licensed Products, and New Indications in the Field, and to research, develop, import, use, sell, offer for sell, and commercialize Licensed Products and New Indications in the Field.
For Novel Target Patents, Licensor grants an exclusive, worldwide, royalty-bearing license under any and all Novel Target Patents that, but for the license granted hereunder, would be infringed by the manufacture, use or sale of Gene Products and other Biotherapeutics, solely to discover, research, develop, import, use, sell, offer for sell, and commercialize Gene Products and Biotherapeutic Products.
A Novel Target means a mammalian orthologue of a Selected Target, which orthologue was identified by or on behalf of Licensor pursuant to work conducted under the Mode of Action Program.
An Unlinked Related Target means a Related Target that, at the time of identification of such target by Licensee or Licensor, is not Known to be a target for drug discovery.
A Biotherapeutic Product means any therapeutic or prophylactic product for treatment or prevention of diseases or conditions in humans that comprises or incorporates an antibody against a Mammalian Target, or an antisense compound based upon a Mammalian Target sequence, or a gene therapy product based upon the sequence of a Mammalian Target.
A Diagnostic Product means a product that facilitates identification of patients having a particular disease or having a predisposition to a particular disease, and/or monitors the prognosis or progression of a disease in a patient, by the detection of either sequence differences in different alleles of a Mammalian Target, or the presence or absence of a certain Mammalian Target, or the presence or absence of the protein product of a certain Mammalian Target.
A Gene Product means any therapeutic or prophylactic product for treatment of humans that comprises or incorporates the gene product of a Mammalian Target or a mutein or fusion protein based thereon.
A Pharmacogenomic Product means a product that is primarily used to select between two or more therapeutic or prophylactic regimens for a human, wherein at least one such therapeutic or prophylactic regimen involves a compound that could be used to treat and/or prevent a disease, and where the selected regimen is judged based on the use of the pharmacogenomic product to be of most likely benefit and/or to do the least harm to a patient, and provided that such selection is made based on the genotype of such human at certain genetic loci (including by detection of certain protein products indicative of the necessary genotype) as determined by use of such product to detect either sequence differences in different alleles of a Mammalian Target, or the presence or absence of a certain Mammalian Target, or the presence or absence of the protein product of a certain Mammalian Target.
The FlyTag Database means the sequence data within the database maintained by Licensor under the name FlyTag as of the Effective Date in the form previously released by Licensor to a contractual partner
IPSCIO Record ID: 203296
Licensor is a biopharmaceutical company which is focused on the discovery, development and commercialization of small molecules which target post-transcriptional control of protein expression, and which owns certain proprietary technologies for developing small molecule drugs by targeting such post transcriptional control mechanisms, including GEMS.
GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.
Gene Expression Modulation by Small-molecules (GEMS) is PTC’s novel and proprietary screening technology for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology modulate gene expression by targeting the post-transcriptional control processes that act through the untranslated regions (UTRs) of messenger RNA (mRNA) molecules.
Parties wish to collaborate on specific therapeutic targets with a focus on cardiovascular, metabolic and addictive diseases, and the discovery of clinical candidate small molecules which act upon such targets.
This agreement pertains to drug discovery.
IPSCIO Record ID: 289175
Active Compound shall mean a Compound that modulates a Target, the mechanism of which is a binding interaction with a Target, having a level of activity against a Target, expressed as an IC50, that is – less than forty (40) nanomolar- as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan; and a Compound that modulates at least two of the following receptors TrkA, TrkB or TrkC, the mechanism of which is a binding interaction with the applicable Trk receptor, having a level of activity against the applicable Trk receptor, expressed as an ICso, that is less than forty (40) nanomolar as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan.
Clinical Candidate shall mean, with respect to each Target or Trk, any Active Compound that meets the Clinical Candidate Criteria set forth in the Discovery Plan.
Compound shall mean any one or more chemical entity(ies) made and tested against Trk in the course of Licensors pan-Trk program prior to the Effective Date, or synthesized by Licensor in the course of performing or in connection with the Discovery Program, in each case together with any salt, hydrate, solvate, clathrate, polymorph or isomer thereof.
Product shall mean any pharmaceutical product incorporating as an active ingredient an Active Compound.
Trk shall mean the Trk family of receptors TrkA, Tr kB and TrkC.
— TrkA shall mean the protein known as UniProtKB/Swiss-Prot # P04629.
— TrkB shall mean the protein known as UniProtKB/Swiss-Prot # Q16620.
— TrkC shall mean the protein known as UniProtKB/Swiss-Prot # Q16288.
The Targets are
— The protein family commonly known as Firbroblast Growth Factor Receptors (FGFR),
— The protein commonly known as [p70S6 Kinase], identified with the following SwissProt entries
a) Ribosomal protein S6 kinase beta-1 (P23443)
b) Ribosomal rotein S6 kinase beta-2 (Q9UBS0]— The protein commonly known as Telomerase reverse transcriptase, identified with the following SwissProt entries
a) Telomerase reverse transcriptase (014746)
b) Telomerase protein component 1 (Q99973)
Licensee possesses pharmaceutical research, development and commercialization capabilities, as well as proprietary technology in the field of cancer treatment.
